Technology
Health
Biotechnology
Catalyst Biosciences
$7.909876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell CBIO and other stocks, options, ETFs, and crypto commission-free!
About
Catalyst Biosciences, Inc. Common Stock, also called Catalyst Biosciences, is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Read More Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.
CEO
Employees
21
Headquarters
South San Francisco, California
Founded
2015
Market Cap
94.60M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
329.48K
High Today
$8.20
Low Today
$7.80
Open Price
$7.88
Volume
32.32K
52 Week High
$26.20
52 Week Low
$6.20
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2015 IPO
US
News
Associated PressMay 2
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation received from the European Commission Initiated DalcA Phase 2b Trial for the Treatment of Hemophilia B SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2019 and provided a corporate update. “We are pl...
Markets InsiderApr 29
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
A single intravitreal injection of 125 μg CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement factor 3 (C3) in non-human primates (NHP), supporting dosing three to four times a year Data support CB 2782-PEG’s potential as a best-in-class anti-C3 ocular therapy SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., April 29, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), and Mosaic Biosciences today announced the presentation of new data on peg...
Price Paid on Robinhood
34% Lower
Right Now
52 Week Low
$6.20
Average Price Paid
$12.05
52 Week High
$26.20
Earnings
-$1.53
-$1.20
-$0.87
-$0.54
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 1, Pre-Market